Jing Zhang
Phamaceutical company focus on innovative drugs including oncology, neurology and autoimmune diseases.
Simcere
ManagerAbby Zhang
大博医疗科技股份有限公司是一家A股上市的综合性医用高值耗材公司。立足于骨科产品的行业优势地位,现已是国内最具成长性的医用高值耗材企业之一。
Double Medical
Investment managerXiaoyuan Zhang
Mabwell, founded in 2017 in Zhangjiang District of Shanghai, is an innovation-based bio-pharmaceutical company with 9 biomedical R&D and manufacturing subsidiaries and a strong, diverse and experienced technical team under its wing. With its world class high-throughput antibody drug discovery platform, well-established pharmaceutical research system and mature process development, the company is dedicated to the R&D and manufacturing of therapeutic monoclonal antibodies, long acting recombinant protein and other new macromolecular drugs. Currently, 30 different drugs for tumor, autoimmunity, infection resistance and ophthalmology are being developed at various stages, among which 1 is cleared for production and 6 are in clinical research with 4 in key clinical stage. Guided by an innovation-driven strategy, the company has actively pushed for commercialization with a production facility built in line with both Chinese and Western GMP standards already up and running in Taizhou, Jiangsu province. Another large-scale industrial base in Shanghai is under construction. The first drug variety will be on the market in 2020 and the number will go up to 4 (or more) in 2023, Mabwell closed series A financing of 1.97 Billion Yuan at April, 2020, demonstrating the company’s ambition to become a leading bio-pharmaceutical enterprise in China.

English (UK)
中文版
Responsive Web Design powered by